PURDUE PHARMA, LP for PURDUE PHARMA LP
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
Monitored activity on bills that seek to improve access to substance use disorder treatment by removing certain barriers to care.: H.R. 1384 - Mainstreaming Addiction Treatment Act of 2021, H.R. 4203 IMPROVE Addiction Care Act, and H.R. 955 / S. 285 Medicaid Reentry Act of 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA | — |
Health Issues HCR
Monitored congressional activity relating to coverage requirements, employer healthcare-related issues, and public health matters relating to pandemic preparedness and response.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA New | — |
Medicare/Medicaid MMM
Monitored congressional activity on legislation to address prescription drug prices in the Medicare and Medicaid programs (H.R. 19 - Lower Costs, More Cures Act of 2021, and H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA | — |
Bankruptcy BNK
Monitored ongoing congressional activity pertaining to bankruptcy reforms and use of non-debtor releases in bankruptcy (H.R. 2096 / S. 2472 and H.R. 4777 / 2497), including outreach regarding committee hearings held on these issues and potential future hearings and activity on the legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.